US85220G1094
US85220G1094
SpyGlass Pharma, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 833.52M EUR | 744.51M EUR | 866.24M EUR | -- |
Enterprise Value | 590.94M EUR | 523M EUR | 628.94M EUR | -- |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -9.27x | -- | -- | -- |
Price to Sales | -- | -- | -- | -- |
Price to Book | 3.59x | 3.2x | 3.46x | -- |
EV/Revenue | -- | -- | -- | -- |
EV/EBITDA | -9.67x | -- | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -- | -6.68% | -4.54% | -- |